Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986651 | 0.81 | MEN1 (0.53) | RAB9AMAPTNPC1GAAMAPK1 | |
| SCHEMBL8721609 | 0.81 | KMT2A (0.45) | RAB9AMAPTNPC1GAAKDM4E | |
| SCHEMBL8725862 | 0.81 | MAPT (0.49) | RAB9AMAPTNPC1GAAKDM4E | |
| SCHEMBL8721612 | 0.81 | BRAF (0.38) | RAB9AMAPTNPC1KDM4EMAPK1 | |
| SCHEMBL6418064 | 0.79 | HPGD (0.54) | RAB9AMAPTNPC1GAAKDM4E | |
| SCHEMBL8721645 | 0.79 | MAPT (0.55) | RAB9AMAPTNPC1GAAKDM4E | |
| SCHEMBL72023 | 0.78 | HSD17B10 (0.50) | RAB9AMAPTGAAKDM4EMAPK1 | |
| SCHEMBL8727112 | 0.78 | ABCG2 (0.46) | RAB9AMAPTNPC1KDM4EKMT2A | |
| SCHEMBL3932390 | 0.76 | NPC1 (0.41) | RAB9AMAPTNPC1GAAKDM4E | |
| SCHEMBL8727089 | 0.76 | MEN1 (0.38) | RAB9AMAPTNPC1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517897-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000817-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-0832091-A1 | C-4' MODIFIED ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040705-A1 | C-4' MODIFIED ADENOSINE KINASE INHIBITORS | GENSIA SICOR (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | RAB9A 4499/4885MAPT 4041/4885NPC1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.